查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595441

多囊性卵巢治療市場：按藥物類別、手術、分銷管道分類 - 全球預測 2025-2030

Polycystic Ovarian Syndrome Treatment Market by Drug Class (Anti-Depressants, Anti-Obesity, Insulin Sensitizing Agents), Surgery (Laparoscopic Ovarian Drilling, Ovarian Wedge Resection), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年多卵巢症候群治療市場價值為32.5億美元，預計2024年將達到34.5億美元，複合年成長率為6.63%，到2030年將達到50.9億美元，預計將達到1000萬美元。

卵巢症候群 (PCOS) 治療市場包括藥品、營養食品和旨在控制月經、不孕和代謝問題等症狀的生活方式干涉措施。 PCOS 的高盛行率推動了這一市場的需求，影響著全球約 5-10% 的育齡婦女，影響著身心健康。用途範圍從荷爾蒙避孕藥和Metformin等胰島素增敏藥物到旨在緩解症狀和促進生育能力的手術選擇。最終用途主要是醫院、生育診所和使用非處方補充品和同類療法療法的個人。

主要市場統計
基準年[2023] 32.5億美元
預測年份 [2024] 34.5億美元
預測年份 [2030] 50.9億美元
複合年成長率（%） 6.63%

影響市場成長的主要因素包括由於診斷方法的改進和醫療保健資訊的可用性的增加而提高了對 PCOS 的認知。此外，個人化醫療的創新和新治療策略的引入為製藥公司解決症狀管理中未滿足的需求提供了潛在的機會。然而，荷爾蒙療法的副作用、缺乏明確的治療方法、高昂的治療費用以及某些地區的社會文化障礙等限制因素給市場擴張帶來了挑戰。

創新領域包括天然和生物同質荷爾蒙療法荷爾蒙療法的開發、促排卵藥物的進步以及體重管理方法的改進。他們也有潛力利用遠端醫療和健康應用程式等數位健康解決方案來提高患者的參與度和合規性。該市場的特點是整體治療方法的新興趨勢，將現代醫學與生活方式調整和替代療法相結合。公司可以透過投資多囊性卵巢症候群遺傳和代謝原因的研究，利用日益成長的消費者對個人化醫療保健解決方案的趨勢。透過開展宣傳活動和教育計劃來提高意識，同時確保可負擔性和可及性，公司可以接觸更多消費者並幫助企業在競爭中成長，不斷發展的醫療保健政策可以為企業提供強力的手段。

市場動態：快速發展的多囊性卵巢症候群治療市場的關鍵市場洞察

多囊性卵巢症候群治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球多囊性卵巢症候群盛行率不斷上升
    • 組合藥物的採用增加
    • 加大組織力度，意識提升
  • 市場限制因素
    • 核准的多囊性卵巢症候群治療藥物
  • 市場機會
    • 正在進行的藥物開發研究和開發計劃
    • 策略聯盟和投資以擴大產能
  • 市場挑戰
    • PCOS治療藥物與治療副作用

波特五力：駕馭多囊性卵巢治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解多囊性卵巢卵巢治療市場的外部影響

外部宏觀環境因素在塑造多囊性卵巢症候群治療市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解多囊性卵巢治療市場的競爭格局

卵巢症候群治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣多囊性卵巢症候群治療市場供應商的績效評估

FPNV 定位矩陣是評估多囊性卵巢症候群治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議描繪卵巢症候群治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對卵巢症候群治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 多囊性卵巢症候群（PCOS）盛行率在全球增加
      • 聯合用藥的採用率增加
      • 加大組織力度，提高人們對 PCOS 的認知
    • 抑制因素
      • 缺乏核准治療多囊性卵巢症候群的藥物
    • 機會
      • 正在進行的藥物開發研究和開發計劃
      • 策略聯盟投資與產能擴張
    • 任務
      • 多囊性卵巢症候群藥物和治療的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的卵巢症候群治療市場

  • 抗憂鬱症
  • 預防肥胖
  • 胰島素增敏劑
  • 口服避孕藥

第7章卵巢手術治療市場

  • 腹腔鏡卵巢穿孔
  • 卵巢楔形切除術

第8章多囊性卵巢治療市場：依分銷管道

  • 藥局
  • 電子商務
  • 不孕不育治療診所
  • 醫院藥房

第9章北美和南美卵巢症候群治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太多囊卵巢卵巢治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲卵巢症候群治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Ferring BV
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-957C47F91255

The Polycystic Ovarian Syndrome Treatment Market was valued at USD 3.25 billion in 2023, expected to reach USD 3.45 billion in 2024, and is projected to grow at a CAGR of 6.63%, to USD 5.09 billion by 2030.

The Polycystic Ovarian Syndrome (PCOS) treatment market encompasses a range of pharmaceuticals, nutraceuticals, and lifestyle interventions aimed at managing symptoms like menstrual irregularities, infertility, and metabolic issues. This market's necessity stems from the high prevalence of PCOS, affecting approximately 5-10% of women of reproductive age globally, with implications for both physical and mental health. Applications extend from hormonal birth control and insulin-sensitizing agents like metformin to surgical options, intended to alleviate symptoms and promote fertility. End-use primarily revolves around hospitals, fertility clinics, and individuals utilizing over-the-counter supplements and homeopathic remedies.

KEY MARKET STATISTICS
Base Year [2023] USD 3.25 billion
Estimated Year [2024] USD 3.45 billion
Forecast Year [2030] USD 5.09 billion
CAGR (%) 6.63%

Key factors influencing market growth include increasing awareness of PCOS among demographics due to enhanced diagnostic procedures and accessible healthcare information. Additionally, innovation in personalized medicine and the introduction of new treatment strategies present potential opportunities for pharmaceutical companies to address the unmet needs in symptom management. However, limitations like side effects of hormonal treatments, lack of definitive cures, high treatment costs, and socio-cultural obstacles in certain regions pose challenges to market expansion.

Areas ripe for innovation include the development of natural and bio-identical hormone therapies, advancements in ovulation-induction medications, and improved methods for weight management. There's also potential in leveraging digital health solutions, such as telemedicine and health apps, for enhanced patient engagement and compliance. The market is characterized by emerging trends in holistic treatment approaches, integrating modern medicine with lifestyle adjustments and alternative therapies. Businesses can capitalize on the growing consumer inclination towards personalized healthcare solutions by investing in research focused on genetic and metabolic drivers of PCOS. Ensuring affordability and accessibility, while creating awareness through campaigns and educational programs, can enable companies to capture a broader audience, offering robust avenues for business growth amid competition and evolving healthcare policies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Polycystic Ovarian Syndrome Treatment Market

The Polycystic Ovarian Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of PCOS worldwide
    • Increasing adoption of combination drugs
    • Rising organizational efforts to create awareness regarding PCOS
  • Market Restraints
    • Lack of approved drugs for PCOS
  • Market Opportunities
    • Ongoing research and development projects for drug development
    • Strategic alliances and investment for capacity expansion
  • Market Challenges
    • Side effects of PCOS drugs and treatment

Porter's Five Forces: A Strategic Tool for Navigating the Polycystic Ovarian Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Polycystic Ovarian Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Polycystic Ovarian Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Polycystic Ovarian Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Polycystic Ovarian Syndrome Treatment Market

A detailed market share analysis in the Polycystic Ovarian Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Polycystic Ovarian Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Polycystic Ovarian Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Polycystic Ovarian Syndrome Treatment Market

A strategic analysis of the Polycystic Ovarian Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Polycystic Ovarian Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Ferring B.V., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Polycystic Ovarian Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anti-Depressants, Anti-Obesity, Insulin Sensitizing Agents, and Oral Contraceptives.
  • Based on Surgery, market is studied across Laparoscopic Ovarian Drilling and Ovarian Wedge Resection.
  • Based on Distribution Channel, market is studied across Drug Stores, E-Commerce, Fertility Clinics, and Hospital Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of PCOS worldwide
      • 5.1.1.2. Increasing adoption of combination drugs
      • 5.1.1.3. Rising organizational efforts to create awareness regarding PCOS
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of approved drugs for PCOS
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development projects for drug development
      • 5.1.3.2. Strategic alliances and investment for capacity expansion
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects of PCOS drugs and treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Polycystic Ovarian Syndrome Treatment Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-Depressants
  • 6.3. Anti-Obesity
  • 6.4. Insulin Sensitizing Agents
  • 6.5. Oral Contraceptives

7. Polycystic Ovarian Syndrome Treatment Market, by Surgery

  • 7.1. Introduction
  • 7.2. Laparoscopic Ovarian Drilling
  • 7.3. Ovarian Wedge Resection

8. Polycystic Ovarian Syndrome Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Drug Stores
  • 8.3. E-Commerce
  • 8.4. Fertility Clinics
  • 8.5. Hospital Pharmacies

9. Americas Polycystic Ovarian Syndrome Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Polycystic Ovarian Syndrome Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Bayer AG
  • 4. Bristol-Myers Squibb Company
  • 5. Eli Lilly and Company
  • 6. Ferring B.V.
  • 7. Johnson & Johnson Services, Inc.
  • 8. Lupin Limited
  • 9. Merck & Co., Inc.
  • 10. Mylan N.V.
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Sanofi S.A.
  • 14. Takeda Pharmaceutical Company Limited
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN SENSITIZING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY LAPAROSCOPIC OVARIAN DRILLING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY OVARIAN WEDGE RESECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023